Shots:
- The company reported the results from a study based on the structural and functional analysis of SB11, a proposed biosimilar referencing Lucentis (ranibizumab)
- The analytical assessment demonstrated that structural, physicochemical characterization i.e. amino acid sequence, post-translational modifications, higher order structure, and size and charge variants of SB11 were similar to Lucentis
- The SB11 is also functionally similar to Lucentis based on a set of bioassays and binding assays covering a broad range of VEGF-related functional activities. SB11 is under review by the US FDA and EMA
Click here to read full press release/ article | Ref: Globenewswire | Image: Twitter
The post Samsung Bioepis Presents Results of SB11 (proposed biosimilar ranibizumab) at ARVO 2021 first appeared on PharmaShots.
